SignalFDA/Bio

Bicara Therapeutics Q2 Net Loss Expands; Phase 3 FORTIFI-HN01 Study Enrollment On Track

Phase 3 enrollment on track offsets wider Q2 net loss, signaling biotech progress.

What changed

Why it matters

Phase 3 enrollment on track offsets wider Q2 net loss, signaling biotech progress.

Sources